🇺🇸 FDA
Patent

US 12228572

Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells

granted A61KA61K31/713A61P

Quick answer

US patent 12228572 (Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells) held by The First Hospital of China Medical University expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The First Hospital of China Medical University
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/713, A61P, A61P31/18